drugset / Trial / NCT05552508

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

NCT05552508

Phase 4 Completed 45 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional Respiratory Imaging (FRI) platform.

Timeline

Start
2022-10-11
Primary completion
2024-07-19
Completion
2024-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Benralizumab Monoclonal antibody 30 mg Subcutaneous

Indications